In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Three-year major clinical outcomes of phosphorylcholine polymer- versus BioLinx polymer-zotarolimus-eluting stents: A propensity score matching study
Topic : interventional cardiology and cardiovascular surgery
Sub-topic : Coronary Intervention: Stents
Session type : Poster Session
Authors : YH Kim (Chuncheon City,KR), A-Y Her (Chuncheon City,KR), S-W Rha (Seoul,KP), BG Choi (Seoul,KP), A Mashaly (Seoul,KP), Y Park (Seoul,KP), WY Jang (Seoul,KP), W Kim (Seoul,KP), JY Choi (Seoul,KP), EJ Park (Seoul,KP), JO Na (Seoul,KP), CU Choi (Seoul,KP), EJ Kim (Seoul,KP), CG Park (Seoul,KP), HS Seo (Seoul,KP)
Purpose: Because there are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZESs) with phosphorylcholine polymer (P)-ZESs. We try to compare the efficacy and safety of B-ZESs with P-ZESs in patients underwent percutaneous coronary intervention (PCI) during 3-year follow-up period.
Methods: Finally, 1254 patients who underwent PCI with P-ZESs (Endeavor® [ZES-E] or Endeavor sprint® [ZES-S], n=356) or B-ZESs (Endeavor resolute® [ZES-R] or Resolute Integrity® [ZES-I], n=889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR) and the secondary endpoint was stent thrombosis (ST) up to 3 years.
Results: After PSM, two propensity-matched (PSM) groups (275 pairs, n=550, C-statistic = 0.730) were generated. During the 3-year follow-up period, the cumulative incidence of total death, cardiac death, MI, total revascularization, TLR, TVR, non-TVR, MACE (HR, 1.525; 95% CI, 0.920–2.526; p=0.101) and ST (HR, 1.248; 95% CI, 0.335–4.4649; p=0.101) were similar between P-ZESs and B-ZESs after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs. 3.8%, log rank p=0.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs. 4.8%, log rank p=0.025) (Figure).
Conclusions: B-ZESs showed comparable safety and efficacy with P-ZESs. However, TLR rate was higher in ZES-S compared to ZES-I, TVR rates were higher in ZES-S compared with ZES-R during 3-year follow-up periods.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease